Upstream Bio, Inc. (UPB) stock
UPBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.78−0.08 (-2.80%)
Close on Nov 13, 2026Market cap $152.26MP/E –Yield –
Upstream Bio operating margin
Operating margin is operating income as a percentage of revenue.
Upstream Bio's operating margin for the twelve months ending Sep 30, 2026 was -6116.0%. For fiscal 2025 it was -5618.8%, against -3281.2% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -5618.8% | −2337.6 |
| FY2024 | Dec 31, 2024 | -3281.2% | −1595.7 |
| FY2023 | Dec 31, 2023 | -1685.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -10982.0% | −5442.6 |
| Q2 FY2026 | Jun 30, 2026 | -5481.0% | −748.1 |
| Q1 FY2026 | Mar 31, 2026 | -4218.1% | +1437.9 |
| Q4 FY2025 | Dec 31, 2025 | -6911.2% | −2617.9 |
| Q3 FY2025 | Sep 30, 2025 | -5539.4% | −2426.9 |
| Q2 FY2025 | Jun 30, 2025 | -4732.9% | −1293.7 |
| Q1 FY2025 | Mar 31, 2025 | -5656.0% | −3310.2 |
| Q4 FY2024 | Dec 31, 2024 | -4293.3% | −1108.9 |
| Q3 FY2024 | Sep 30, 2024 | -3112.5% | −1601.1 |
| Q2 FY2024 | Jun 30, 2024 | -3439.2% | – |
| Q1 FY2024 | Mar 31, 2024 | -2345.8% | – |
| Q4 FY2023 | Dec 31, 2023 | -3184.4% | – |
| Q3 FY2023 | Sep 30, 2023 | -1511.4% | – |
See a number that looks wrong?